HC Wainwright Issues Pessimistic Estimate for MDGL Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Stock analysts at HC Wainwright decreased their Q1 2025 EPS estimates for shares of Madrigal Pharmaceuticals in a note issued to investors on Thursday, February 27th. HC Wainwright analyst E. Arce now expects that the biopharmaceutical company will earn ($2.83) per share for the quarter, down from their prior forecast of ($2.10). HC Wainwright currently has a “Buy” rating and a $405.00 target price on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q2 2025 earnings at ($2.14) EPS, Q3 2025 earnings at ($1.64) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($7.82) EPS, FY2026 earnings at $9.85 EPS, FY2027 earnings at $31.36 EPS, FY2028 earnings at $52.07 EPS and FY2029 earnings at $87.27 EPS.

Several other research firms have also recently weighed in on MDGL. Cantor Fitzgerald reissued a “neutral” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 20th. Citigroup boosted their price objective on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a “buy” rating in a report on Thursday, February 27th. B. Riley raised shares of Madrigal Pharmaceuticals from a “hold” rating to a “strong-buy” rating and raised their target price for the stock from $236.00 to $422.00 in a report on Thursday, February 27th. Finally, JMP Securities reissued a “market outperform” rating and set a $427.00 price target on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $375.75.

Madrigal Pharmaceuticals Stock Performance

NASDAQ MDGL opened at $321.32 on Monday. The stock has a market cap of $7.09 billion, a PE ratio of -12.81 and a beta of -0.38. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. The firm has a 50-day moving average of $323.17 and a 200-day moving average of $286.30. Madrigal Pharmaceuticals has a 52-week low of $189.00 and a 52-week high of $377.46.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share for the quarter, beating the consensus estimate of ($4.32) by $1.61. The firm had revenue of $103.32 million during the quarter, compared to the consensus estimate of $97.81 million.

Insider Activity at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, CEO William John Sibold sold 1,584 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $335.24, for a total value of $531,020.16. Following the transaction, the chief executive officer now directly owns 54,303 shares in the company, valued at $18,204,537.72. The trade was a 2.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Rebecca Taub sold 1,689 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $273.41, for a total transaction of $461,789.49. Following the sale, the chief marketing officer now owns 457,310 shares of the company’s stock, valued at approximately $125,033,127.10. The trade was a 0.37 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,787 shares of company stock valued at $7,351,029. 22.80% of the stock is owned by corporate insiders.

Institutional Trading of Madrigal Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new position in Madrigal Pharmaceuticals during the fourth quarter valued at approximately $141,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Madrigal Pharmaceuticals by 23.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 27,538 shares of the biopharmaceutical company’s stock worth $8,497,000 after buying an additional 5,182 shares in the last quarter. Woodline Partners LP raised its holdings in shares of Madrigal Pharmaceuticals by 110.2% in the 4th quarter. Woodline Partners LP now owns 309,117 shares of the biopharmaceutical company’s stock valued at $95,384,000 after acquiring an additional 162,027 shares in the last quarter. Vestal Point Capital LP boosted its position in shares of Madrigal Pharmaceuticals by 216.7% during the 4th quarter. Vestal Point Capital LP now owns 95,000 shares of the biopharmaceutical company’s stock valued at $29,314,000 after acquiring an additional 65,000 shares during the last quarter. Finally, Soleus Capital Management L.P. purchased a new position in shares of Madrigal Pharmaceuticals during the fourth quarter worth about $3,363,000. 98.50% of the stock is currently owned by institutional investors.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.